-- Worldwide knee sales increased 20% (16% constant currency)

-- Worldwide hip sales increased 18% (13% constant currency)

-- Adjusted EBITDA increased 15% to $207 million

During the first quarter of fiscal year 2009, net sales increased 13% to $607.0 million from $537.3 million for the "combined" period last year. Excluding the impact of foreign currency, net sales increased 9% during the first quarter. U.S. sales increased 9% to $368.4 million during the quarter; Europe sales increased 19% (7% constant currency) to $169.4 million; and sales for International (which primarily includes Canada, South America, Mexico and the Pacific Rim) increased 20% (13% constant currency) to $69.2 million.

On a reported basis, operating income for the first quarter of fiscal year 2009 was $57.0 million, compared to an operating loss of $539.3 million for last year's "combined" period. Excluding special charges in both periods, adjusted operating income was $171.6 million for the first quarter of fiscal 2009 compared to $153.4 million for the "combined" period last year, resulting in an increase of 12%. Adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA") for the first quarter of fiscal year 2009 was $207.0 million or 34.1% of sales compared to adjusted EBITDA of $180.7 million or 33.6% of sales in the "combined" period last year, an increase of 15%.

Biomet reported $114.6 million of special items (pre-tax) during the first quarter of fiscal year 2009, including purchase accounting charges of $96.0 million. The purchase accounting charges primarily relate to amortization expense for established intangible assets, along with depreciation expense as a result of the step-up of property to fair value. The remaining special items of $18.6 million primarily include stock compensation expense of $7.2 million and $6.0 million of costs associated with the previously announced operational improvement program.

Net interest expense for the first quarter of fiscal year 2009 was $141.1 million compared to $80.7 million in the "combined" period last year. Net debt at the end of the first quarter of fiscal year 2009 was $6,073.8 million, a decrease from the Merger Date of $88.2 million, which reflects $78.0 million of principal payments and an increase in cash of $87.0 million, offset by $77.0 million of unfavorable currency movement on our Euro-denominated Term Loan. A reconciliation of reported results to adjusted results is included in this press release, which is also posted on our website: www.biomet.com

Biomet's President and Chief Executive Officer Jeffrey R. Binder commented, "The first quarter of fiscal 2009 marked our fifth consecutive quarter of double-digit global reconstructive device sales on a constant currency basis. Our strong growth in the reconstructive product category was a result of excellent sales of hips and knees across all geographies. In addition, I was pleased with the performance of our sports medicine business, which was fueled by new product sales."

Mr. Binder continued, "I was also encouraged that we were able to deliver leverage on the bottom line with adjusted EBITDA growth of 15%. Overall, we had a solid first quarter and a strong start to fiscal year 2009."

First Quarter Sales Performance

                Worldwide             Worldwide     Worldwide     United
                Reported              Reported      CC            States
                Quarter 1 - 2009      Growth%       Growth%       Growth%
Reconstructive  $         449.3       16    %       12    %       13   %
Knees                                 20    %       16    %       16   %
Hips                                  18    %       13    %       14   %
Dental                                5     %       -1    %       -7   %
Other                                 15    %       10    %       14   %
Fixation                  60.2        3     %       1     %       -6   %
Spine                     51.3        -4    %       -6    %       2    %
Other                     46.2        19    %       16    %       20   %
Total Sales     $         607.0       13    %       9     %       9    %

During the first quarter, the Oxford(R) Partial Knee System and both primary and revision components of the Vanguard(TM) Complete Knee System continued to drive knee sales growth. The Oxford(R) System remains the only free-floating mobile-bearing partial knee approved by the U.S. Food and Drug Administration. The Vanguard(TM) Knee offers complete component interchangeability, allows for sizing of the femur and tibia independently, and offers implant combinations than any other knee system available.

Numerous products contributed to the strong first quarter growth in hip sales, including the conventional and Microplasty(TM) versions of the Taperloc(R) Hip Stem, the M2a-Magnum(TM) Acetabular System, E-Poly(TM) Acetabular Liners, and the Regenerex(R) Ringloc(R)+ Modular Acetabular System, in addition to European sales of the Aura(R) Hip Stem and the Exceed ABT(TM) (Advanced Bearing Technologies) Acetabular System.

Worldwide dental reconstructive device sales during the first quarter of fiscal year 2009 decreased 1% at constant currency, coming off of a very strong fourth quarter of fiscal year 2008.

The craniomaxillofacial fixation and internal fixation product categories reported double-digit growth during the first quarter, while electrical stimulation and external fixation sales decreased. U.S. spine sales growth was assisted by mid single-digit growth in domestic sales of spinal implants and orthobiologics for the spine. In the other products category, sales of softgoods and bracing products decreased during the first quarter of fiscal year 2009, while sports medicine devices experienced strong demand.

All trademarks herein are the property of Biomet, Inc. or its subsidiaries unless otherwise indicated.

Financial Schedule Presentation

The Company's unaudited condensed consolidated financial statements as of and for the three months ended August 31, 2008 and for the periods June1 to July11, 2007 (Predecessor) and July12 to August 31, 2007 (Successor) and other financial data included in this press release have been prepared in a manner that complies, in all material respects, with generally accepted accounting principles in the United States and reflects certain purchase accounting adjustments related to the Merger.

In this press release and related website schedules, the June1 to July11, 2007 (Predecessor) and July12 to August 31, 2007 (Successor) periods have been combined and are referred to as "combined". The combined presentation does not comply with U.S. GAAP, but is presented because we believe it provides the most meaningful comparison of our results. The results of the Successor are not comparable to the results of the Predecessor due to the difference in basis of presentation of purchase accounting as compared to historical cost.

About Biomet

Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet's product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, autologous therapies and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in approximately 90 countries.

The Transaction

Biomet Inc. finalized the merger with LVB Acquisition Merger Sub, Inc., a wholly-owned subsidiary of LVB Acquisition, Inc. on September25, 2007. LVB Acquisition, Inc. is indirectly owned by investment partnerships directly or indirectly advised or managed by The Blackstone Group L.P., Goldman Sachs& Co., Kohlberg Kravis Roberts& Co. L.P. and TPG Capital.

Contacts

For further information contact Daniel P. Florin, Senior Vice President and Chief Financial Officer at (574)372-1687 or Barbara Goslee, Director, Corporate Communications at (574)372-1514.

Forward-Looking Statements

The is press release contains "forward-looking statements" within the meaning of Section27A of the Securities Act of 1933 and Section21E of the Securities Exchange Act of 1934, as amended. Those statements are often indicated by the use of words such as "will," "intend," "anticipate," "estimate," "expect," "plan" and similar expressions. Forward-looking statements involve certain risks and uncertainties. Actual results may differ materially from those contemplated by the forward looking statements due to, among others, the following factors: the results of ongoing investigations by the United States Department of Justice; the ability to successfully implement new technologies; the Company's ability to sustain sales and earnings growth; the Company's success in achieving timely approval or clearance of its products with domestic and foreign regulatory entities; the stability of certain foreign economic markets; the impact of anticipated changes in the musculoskeletal industry and the ability of the Company to react to and capitalize on those changes; the ability of the Company to successfully implement its desired organizational changes; the impact of the Company's managerial changes; and other factors set forth in the Company's filings with the SEC, including the Company's most recent annual report on Form 10-K (as amended) and quarterly reports on Form 10-Q. Although the Company believes that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or non-occurrence of future events. There can be no assurance as to the accuracy of forward-looking statements contained in this press release. The inclusion of a forward-looking statement herein should not be regarded as a representation by the Company that the Company's objectives will be achieved. The Company undertakes no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements which speak only as of the date on which they were made.

Biomet, Inc.
Product Sales
Three Month Period Ended August 31, 2008
(In millions, unaudited)
                                                                                        Constant
                                        (Combined)(1)       Reported                    Currency
                2009                    2008                Growth %                    Growth %
Reconstructive  $ 449.3                 $ 386.5             16.2                   %    11.9           %
Fixation        60.2                    58.5                2.9                    %    1.3            %
Spine           51.3                    53.5                (4.1              )    %    (5.6      )    %
Other           46.2                    38.8                19.1                   %    15.6           %
Total           $ 607.0                 $ 537.3             13.0                   %    9.3            %
                Sales Growth            FX                  Sales Growth in
                As Reported             Impact              Local Currencies
Reconstructive  16.2               %    4.3            %    11.9                   %
Fixation        2.9                %    1.6            %    1.3                    %
Spine           (4.1          )    %    1.5            %    (5.6              )    %
Other           19.1               %    3.5            %    15.6                   %
Total sales     13.0               %    3.7            %    9.3                    %
(1) See Non-GAAP Financial Measures
Disclosure Below

(1)Non-GAAP Financial Measures:

Management uses non-GAAP financial measures, such as net sales, excluding the impact of foreign currency (constant currency), operating income as adjusted, net income as adjusted, Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA (as defined by our bank agreement, the method to calculate this is likely to be different from methods used by other companies). In addition, information for the period from June 1 to July 11, 2007 ("Predecessor" and the date which the merger of Biomet with a company owned by a consortium of private equity funds occurred, with Biomet as the surviving entity) and from July 12, 2007 and thereafter (Successor) periods have been combined and are referred to as "combined" in the press release and attached statements. The combined presentation does not comply with U.S. GAAP, but is presented because we believe it provides the most meaningful comparison of our results. The results of the Successor are not comparable to the results of the Predecessor due to the difference in basis of presentation of purchase accounting as compared to historical cost. The term "as adjusted", a non-GAAP financial measure, refers to financial performance measures that exclude certain income statement line items, such as interest, taxes, depreciation or amortization and/or exclude certain expenses as defined by our bank agreement, such as restructuring charges, integration and facilities opening costs or other business optimization expenses, new systems design and implementation costs, certain start-up cots and costs related to consolidation of facilities, certain non-cash charges, advisory fees paid to the private equity owners, certain severance charges, purchase accounting costs, costs associated with stock option accounting issues, payments to distributors that are not in the ordinary course of business and other related charges. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. Management uses these measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to team member performance compensation targets, including equity incentives. Investors should consider these non-GAAP measures only supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP in the United States.

Biomet, Inc.
Geographic Segment Sales Percentage Summary
Three Month Period Ended August 31, 2008
(In millions, unaudited)
                                                                                              Constant
                                                   (Combined)(1)       Reported               Currency
                                2009               2008                Growth %               Growth %
Geographic Segments:
            United States       $ 368.4            $ 336.8             9.4               %    9.4       %
            Europe              169.4              142.6               18.8              %    7.3       %
            International       69.2               57.9                19.5              %    12.7      %
            Total               $ 607.0            $ 537.3             13.0              %    9.3       %
                                Sales Growth       FX                  Sales Growth in
                                As Reported        Impact              Local Currencies
            United States       9.4           %    -              %    9.4               %
            Europe              18.8          %    11.5           %    7.3               %
            International       19.5          %    6.8            %    12.7              %
            Total sales         13.0          %    3.7            %    9.3               %
(1) See Non-GAAP Financial Measures
Disclosure above

Biomet, Inc.
As Reported Consolidated Statements of Operations
(In millions, unaudited)
                                                                       (Successor)                     (Predecessor)
                                          (Successor)                  Period from                     Period from
                                          Three Months Ended           July 12, 2007 to                June 1, 2007 to
                                          August 31, 2008              August 31, 2007                 July 11, 2007
Net sales                                 $       607.0                $      288.6                    $      248.8
Cost of sales                                     181.5                       106.8                           102.3
Gross profit                                      425.5                       181.8                           146.5
Gross profit percentage                           70.1    %                   63.0    %                       58.9   %
Selling, general and administrative               253.5                       187.3                           194.2
Research and development                          23.5                        13.6                            34.0
In-process research and development               -                           392.8                           -
Amortization                                      91.5                        45.2                            0.5
Operating income (loss)                           57.0                        (457.1  )                       (82.2  )
Percentage of Sales                               9.4     %                   -158.4  %                       -33.0  %
Other income (expense), net                       (9.0    )                   5.4                             0.6
Interest expense, net                             (141.1  )                   (80.4   )                       (0.3   )
Income (loss) before income taxes                 (93.1   )                   (532.1  )                       (81.9  )
Income taxes                                      (33.2   )                   (49.9   )                       (27.3  )
Tax rate                                          35.7    %                   9.4     %                       33.3   %
Net income (loss)                         $       (59.9   )            $      (482.2  )                $      (54.6  )
Percentage of Sales                               -9.9    %                   -167.1  %                       -21.9  %
(1) See Non-GAAP Financial Measures
Disclosure above

BIOMET, INC.
Other Financial Information
Operating Income to Adjusted Operating Income
(in millions, unaudited)
                                                                                                     (Combined)(1)
                                                                      Three Months Ended             Three Months Ended
                                                                      August 31, 2008                August 31, 2007
Operating income, as reported                                         $       57.0                   $       (539.3  )
Purchase acccounting depreciation                                             4.5                            1.7
Purchase accounting amortization                                              91.5                           45.2
Additional cost of sales for inventory write up to fair value                 -                              28.9
In-process research and development                                           -                              392.8
Share-based payment                                                           7.2                            112.8
Distributor agreements                                                        2.0                            38.6
Department of Justice (monitoring expense)                                    1.2                            26.9
Consulting expenses related to operational improvement                        6.0                            4.4
initiatives, and other related costs
Sponsor fee                                                                   1.9                            -
Investment banker fee                                                         -                              29.6
Additional legal/merger related fees                                          -                              11.8
Other                                                                         0.3                            -
Operating income, as adjusted                                         $       171.6                  $       153.4
(1) See Non-GAAP Financial Measures
Disclosure above

BIOMET, INC.
Other Financial Information
EBITDA and adjusted EBITDA - August 31, 2008
(in millions, unaudited)
                                                                                                   (Combined)(1)
                                                                     Three Months Ended            Three Months Ended
                                                                     August 31, 2008               August 31, 2007
Operating income, as reported                                        $       57.0                  $       (539.3  )
Historical depreciation                                                      35.4                          26.8
Purchase acccounting depreciation                                            4.5                           1.7
Historical amortization                                                      -                             0.5
Purchase accounting amortization                                             91.5                          45.2
EBITDA, as reported                                                  $       188.4                 $       (465.1  )
Special items and purchase accounting adjustments:
Additional cost of sales for inventory write up to fair value                -                             28.9
In-process research and development                                          -                             392.8
Share-based payment                                                          7.2                           112.8
Distributor agreements                                                       2.0                           38.6
Department of Justice (monitoring expense)                                   1.2                           26.9
Consulting expenses related to operational improvement                       6.0                           4.4
initiatives, and other related costs
Sponsor Fee                                                                  1.9                           -
Investment banker fee                                                        -                             29.6
Additional legal/merger related fees                                         -                             11.8
Other                                                                        0.3                           -
EBITDA, as adjusted                                                  $       207.0                 $       180.7
(1) See Non-GAAP Financial Measures
Disclosure above

BIOMET, INC.
Other Financial Information
Net Income (Loss) to EBITDA, as reported
(in millions, unaudited)
                                                                     (Combined)(1)
                                      Three Months Ended             Three Months Ended
                                      August 31, 2008                August 31, 2007
Net income (loss), as reported        $     (59.9  )                 $       (536.8  )
Depreciation                                39.9                             28.5
Amortization                                91.5                             45.7
Interest expense, net                       141.1                            80.7
Other income (expense), net                 9.0                              (6.0    )
Income taxes                                (33.2  )                         (77.2   )
EBITDA, as reported                   $     188.4                    $       (465.1  )
(1) See Non-GAAP Financial Measures
Disclosure above

BIOMET, INC.
Reconciliation of GAAP Consolidated Net Income (Loss) to
Non-GAAP Adjusted Consolidated Net Income
(In millions, unaudited)
                                                                             (Successor)                     (Combined)(1)
                                                                             Three Months Ended              Three Months Ended
                                                                             August 31, 2008                 August 31, 2007
Net income (loss), as reported                                               $       (59.9   )               $       (536.8  )
Purchase acccounting depreciation                                                    4.5                             1.7
Purchase accounting amortization                                                     91.5                            45.2
Additional cost of sales for inventory write up to fair value                        -                               28.9
In-process research and development                                                  -                               392.8
In-the-money stock option settlement                                                 -                               112.8
Investment banker fee                                                                -                               29.6
Share-based payment                                                                  7.2                             -
Additional legal/merger related fees                                                 -                               11.8
Distributor agreements                                                               2.0                             38.6
Consulting expenses related to operational improvement initiatives,                  6.0                             4.4
and
other related costs
Department of Justice (monitoring expense and settlement payment)                    1.2                             26.9
Sponsor fee                                                                          1.9                             -
Other                                                                                0.3                             -
Tax effect on special and purchase accounting items                                  (40.9   )                       (108.4  )
Net income, as adjusted (Non-GAAP)                                           $       13.8                    $       47.5
(1) See Non-GAAP Financial Measures
Disclosure above

Biomet, Inc.
Balance Sheet
(In millions, unaudited)
                                                     August 31, 2008                      May 31, 2008
Assets
Cash and cash equivalents                            $        143.4                       $        127.6
Accounts receivable, net                                      469.0                                486.2
Income tax receivable                                         48.8                                 48.8
Inventories                                                   545.0                                539.7
Current deferred income taxes                                 96.2                                 100.7
Prepaids and other current assets                             39.9                                 46.7
Property, plant and equipment, net                            628.9                                640.9
Investments                                                   38.7                                 41.3
Intangible assets, net                                        6,009.2                              6,208.2
Goodwill                                                      5,320.1                              5,422.8
Other assets                                                  158.5                                118.9
Total Assets                                         $        13,497.7                    $        13,781.8
Liabilities and Stockholders' Equity
Current liabilities                                  $        377.2                       $        408.2
Accrued Interest                                              149.3                                80.9
Short-term borrowings                                         77.4                                 75.4
Long-term debt                                                6,139.8                              6,225.4
Deferred income taxes                                         2,064.9                              2,112.5
Other Long-term liabilities                                   40.0                                 43.1
Stockholders' equity                                          4,649.1                              4,836.3
Total Liabilities and Stockholders' Equity           $        13,497.7                    $        13,781.8
Net Debt (a)(1)                                      $        6,073.8                     $        6,173.2
(a) Net debt is the sum of cash and cash equivalents and
short-term investments less total debt.
(1) See Non-GAAP Financial Measures
Disclosure above

Biomet, Inc.
Preliminary Consolidated Statements of Cash Flows
(In millions, unaudited)
                                                                       (Successor)               (Successor)                     (Predecessor)
                                                                       Three Months              Period from                     Period from
                                                                       Ended                     July 12, 2007                   June 1, 2007
                                                                       August 31, 2008           to                              to
                                                                                                 August                          July
                                                                                                 31, 2007                        11, 2007
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss                                                               $      (59.9  )           $     (482.2    )               $     (54.6  )
Adjustments to reconcile net loss to net cash from operating
activities:
Depreciation and amortization                                                 131.4                    68.5                            9.3
Amortization of deferred financing costs                                      2.8                      -                               -
In-process research and development charge                                    -                        392.8                           -
Stock based compensation expense                                              7.2                      -                               -
Inventory step-up related to merger                                           -                        28.9                            -
Provision for accounts receivable                                             5.9                      -                               -
Loss (gain) and impairment on investments, net                                2.9                      -                               (7.0   )
Provision for inventory obsolescence                                          8.2                      -                               -
Deferred income taxes                                                         (31.6  )                 (89.2     )                     76.7
Excess tax benefit from exercise of stock options                             -                        -                               (3.9   )
Other                                                                         0.7                      -                               -
Changes in operating assets and liabilities, net of effects from
acquisition:
Accounts receivable                                                           (1.4   )                 30.7                            5.8
Inventories                                                                   (26.6  )                 (10.0     )                     (12.0  )
Prepaid expenses                                                              6.0                      79.7                            -
Accounts payable                                                              (17.7  )                 4.9                             (1.6   )
Accrued (refundable) income taxes                                             (8.2   )                 4.5                             -
Accrued interest                                                              68.8                     41.7                            -
Share-based compensation accrual related to Merger                            -                        (103.0    )                     112.8
Other                                                                         (22.6  )                 63.0                            (66.1  )
Net cash provided by operating activities                                     65.9                     30.3                            59.4
CASH FLOWS FROM INVESTING ACTIVITIES:
Net proceeds from sale and purchase of investments                            -                        125.0                           42.8
Capital expenditures                                                          (41.0  )                 (37.7     )                     (22.0  )
Acquisitions, net of cash acquired                                            (2.0   )                 -                               (9.8   )
Acquisition of Biomet, Inc.                                                   -                        (9,568.5  )                     -
Net cash provided by (used in) investing activities                           (43.0  )                 (9,481.2  )                     11.0
CASH FLOWS FROM FINANCING ACTIVITIES:
Debt:
Proceeds (payments) under amended revolving credit agreement                  3.2                      (39.6     )                     0.2
Payments under senior secured credit facility                                 (9.3   )                 -                               -
Proceeds from long-term debt - merger                                         -                        4,181.0                         -
Payment of deferred financing costs                                           -                        (87.1     )                     -
Equity:
Capital contributions                                                         0.2                      5,387.5                         -
Purchase of common shares                                                     (0.2   )                 -                               (2.8   )
Excess tax benefit from exercise of stock options                             -                        -                               3.9
Net cash provided by (used in) financing activities                           (6.1   )                 9,441.8                         1.3
Effect of exchange rate changes on cash                                       (1.0   )                 -                               0.1
Increase (decrease) in cash and cash equivalents                              15.8                     (9.1      )                     71.8
Cash and cash equivalents, beginning of period                                127.6                    176.9                           105.1
Cash and cash equivalents, end of period                               $      143.4              $     167.8                     $     176.9

BIOMET, INC.
Other Financial Information
GAAP Operating Cash Flow to Adjusted Free Cash Flow and
Unlevered Adjusted Free Cashflow - August 31, 2008
(in millions, unaudited)
                                                                     Three Months Ended
                                                                     August 31, 2008
Operating Cash Flow, as reported                                     $            65.9
Add backs:
Change in accrued (refundable) income taxes                                       40.9
Other income and expense                                                          9.0
Interest expense                                                                  141.1
Special items:
Share-based payment                                                               7.2
Distributor agreements                                                            2.0
Department of Justice (monitoring expense)                                        1.2
Consulting expenses related to operational improvement                            6.0
initiatives, and other related costs
Sponsor Fee                                                                       1.9
Other                                                                             0.3
Deductions:
Change in other non-cash items                                                    (28.3        )
Income tax benefit                                                                (33.2        )
Change in accrued interest                                                        (68.8        )
Capital expenditures                                                              (41.0        )
Adjusted Free Cash Flow                                              $            104.2
Special charges                                                                   (11.3        )
Cash paid for taxes                                                               (6.3         )
Earn-out payments to Europe distributors                                          (2.0         )
Other                                                                             6.2
Unlevered Adjusted Free Cash Flow                                    $            90.8
(1) See Non-GAAP Financial Measures
Disclosure above

SOURCE: Biomet, Inc.

Biomet, Inc. 
Daniel P. Florin, 574-372-1687 
Senior Vice President and Chief Financial Officer 
or 
Barbara Goslee, 574-372-1514 
Director, Corporate Communications

Biomet, Inc. and its subsidiaries design, manufacture, and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet's product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, autologous therapies and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 90 countries.

SOURCE: Biomet, Inc.

Biomet, Inc. 
Carolyn Beatty, Investor Relations, 574-372-1571 
Barbara Goslee, Corporate Communications, 574-372-1514

http://www.reportlinker.com/p090647/World-Orthopedic-Prosthetics-Market.html

This report analyzes the worldwide markets for Orthopedic Prosthetics in Millions of US$. The specific product segments analyzed are Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis, & Other Secondary Joint Prosthesis). The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, Latin America, and Rest of World. Annual forecasts are provided for each region for the period of 2001 through 2015. A ten-year historic analysis is also provided for these markets with annual market analytics. The report profiles 64 companies including many key and niche players worldwide such as Biomet Inc., Corin Group PLC, DePuy Orthopedics Inc., DJO Surgical, Smith & Nephew PLC, Stryker Corp., Wright Medical Group Inc., and Zimmer Holdings Inc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

ORTHOPEDIC PROSTHETICS MCP-3224 A GLOBAL STRATEGIC BUSINESS REPORT

CONTENTS

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3 Hip Prosthesis I-3 Knee Prosthesis I-4 Secondary Joint Prosthesis I-4

II. EXECUTIVE SUMMARY

1. Global Market Overview and Analysis II-1 Current and Future Analysis II-1 Major Growth Drives for the Industry II-1 Growing Obese Population Drives Demand for Joint Replacement Surgeries II-2 Rising Life Expectancy & Active Lifestyle Drive Demand for Joint Replacement Procedures II-2 Cost Containment Issues II-2 Developing Markets Hold Enormous Growth Potential II-2 Revision Procedures Buoy Growth II-3 Minimally Invasive Surgery - Attracts Attention II-3 Demand for Premium Implants Continues II-3 Growing Demand for Total Hip Replacement in Young People II-3 Hip Resurfacing Replacement - for Younger Generation II-4 Gender-Specific Orthopedic Devices Gain Momentum II-4

2. Competitive Scenario II-5 Mergers and Acquisitions Timeline in the Worldwide Orthopedic Prosthetics Industry: 1997-2006 II-5

Table 1: Leading Players in Worldwide Orthopedic Prosthetics/Reconstructive Market (2005): Percentage Breakdown of Value Sales for Zimmer, DePuy (J&J), Stryker, Biomet, Smith & Nephew, and Others (includes corresponding Graph/Chart) II-6

Table 2: Leading Players in Worldwide Hip Prosthesis Market (2004-2006): Percentage Breakdown of Dollar Sales by Company for Zimmer,J&J DePuy, Stryker, Biomet, Smith & Nephew, Wright Medical, and Others (includes corresponding Graph/Chart) II-6

Table 3: Leading Players in Worldwide Knee Prosthesis Market (2004-2006): Percentage Breakdown of Dollar Sales by Company for Zimmer Holdings, J&J DePuy, Stryker Corporation, Biomet, Smith & Nephew, and Others (includes corresponding Graph/Chart) II-7

Table 4: Leading Players in World Market for Extremities (2004-2006E) - Percentage Share Breakdown of Dollar Sales by Company for DePuy, Zimmer, Stryker, Biomet, Smith & Nephew Orthopedics, and Others (includes corresponding Graph/Chart) II-7 Peer Group Analysis II-8 Zimmer Holdings, Inc. II-8 DePuy, Inc. II-8 Stryker Corp. II-9 Biomet, Inc. II-9 Smith& Nephew, Inc. II-10

3. Foreword to the Orthopedic Industry II-11 Mergers and Acquisitions in the Worldwide Orthopedics Industry: 1997-2007 II-11 Orthopedic Orthotics & Prosthetics II-12

Table 5: Global Orthopedic Market (2005): Percentage Breakdown of Value Sales for Reconstructive Joint Replacement, Spine, Trauma and Craniomaxillofacial, Operating Room Equipment, Orthobiologics, Arthroscopy, and Others (includes corresponding Graph/Chart) II-12

4. Orthopedic Prosthetics- Product Overview II-13 Hip Prostheses II-13 Total Hip Replacement II-13 Conditions Requiring Total Hip Replacement II-13 Materials Used... II-14 Cemented Hip Implants II-14 Cementless Hip Implants II-14 Complications Following THR II-14 Partial Hip Replacement II-14 Revision Hip Procedures II-14 Types of Hip Implants II-15 Ceramic-on-Ceramic II-15 Metal-on-Metal II-15 Highly Cross-Linked Polyethylene II-16 Ceramic-on-Polyethylene II-16 Metal-on-Polyethylene II-16 Product Portfolio of Major Players in the Hip Implants Market II-16 Knee Prostheses II-16 Functional Aspects of the Knee II-17 Implant Design II-17 Unicondylar Knee Replacements II-17 Fixed and Mobile Bearing Knees II-18 Mobile Bearing Total Knee Replacement Prostheses II-18 Revision Surgeries II-18 Secondary Joint Prostheses II-18 Shoulder Prosthesis II-19 Ankle Prosthesis II-19 Elbow Prosthesis II-19 Finger Prosthesis II-19

5. Product Trends II-20 Alternate-Bearing Materials in the Hip Implants Market II-20 Diamond-on-Diamond Technology II-20 Cementless Procedures Gain Ground II-20 Trabecular Metal Technology II-21 Surface Modification Technology II-21 Novel Minimally Invasive Approaches II-21 Zimmer Launches Quad-Sparing Total Knee Replacement II-21 Zimmer Launches New Minimally Invasive Hip Procedure Hip Procedure II-21 DePuy Orthopaedics Introduces New Mini-Incision Technique in Hip Replacement II-22

6. Major Prosthesis Technologies - An Overview II-23 Artificial Disc Technology II-23 Artificial Total Disc II-24 Allografts II-25 Osteoinductive Agents/Bone Graft Factors II-25 The Hip Hinge Technology II-26 Resorbables II-26 Cell Therapy - Chondrocyte Transplantation II-26

7. Recent Technological Developments II-27 Innovative Joint Prosthesis Developed II-27 US-Based Inventor Designs New Knee Prosthesis II-27 US Inventors Develop New Modular Prosthetic Knee System II-27 Californian Inventor Develops Orthopedic Implant Surface Configuration II-27 Indiana Inventor Designs New Prosthetic Implant II-27 New Orthopedic Implant Application Method Developed II-27 US-Based Inventors Develops Stem Extension for Leg and Knee Implants II-28 US-Based Inventor Develops New Prosthesis Hip Implant II-28

8. Product Innovations/Introductions II-29 FDA Grants Approval for DJO's X-alt(TM) Polyethylene Liner II-29 Smith & Nephew Introduce R3? Acetabular System II-29 Smith & Nephew Introduces VERILAST? Knee Replacement Technology II-29 Exactech to Launch New Cartilage Repair Technology II-29 Wright Medical Expands Orthopedic Hip Offerings II-29 Zimmer Holdings Introduces Zimmer(R) DTO(TM) Implants II-30 Japan Regulatory Approves Wright's CONSERVE(R) Plus II-30 Smith & Nephew Rolls Out Globally JOURNEY? DEUCE? Knee System II-30 Wright Extends its Hip Product Offerings II-30 FDA Approves Cormet(TM) Hip Resurfacing System of Corin II-31 Exactech Gains FDA Clearance for its Novation(TM) Ceramic AHS(TM) Hip System II-31 Biomet to Roll Out Minimally Invasive Hip Stems II-31 Wright Launches EVOLVE(R) PROLINE System II-31 AIC Receives CE Mark Approval for its New AIC Hip Buffer(TM) Polymer Implant II-32 Portland Gains FDA Approval to Market Beacon Primary Knee System in the US II-32 Portland Develops a New Cemented Hip Replacement Product II-32 Smith and Nephew Receives FDA Clearance to Market Birmingham Hip Brand in the US II-32 Kobayashi Rolls Out New Kiapex Hip Prosthesis System II-33 ABS Gains FDA and CE Mark Approvals for its OrthoGlide Medial Knee Implant II-33 FDA Approves Biomet's Regenerex(TM) Porous Titanium Construct Acetabular System II-33 Smith & Nephew Introduces New JOURNEY* Bi-Cruciate Stabilized Knee System II-33 Wright Medical Unveils New CLAWT Plate for Foot & Ankle Reconstructive Surgeries II-34 Wright Medical Introduces New PROFEMUR(R) RENAISSANCE(TM) Total Hip System II-34 Wright Medical Group Rolls Out A-CLASS(TM) Polyethylene Liner for LINEAGE(R) Hip Implants II-34 FDA Grants PMA Clearance for Zimmer's Trilogy AB(R) Ceramic-on- Ceramic Acetabular System II-34 Zimmer Develops Implant Systems Based on Trabecular Metal Technology II-34 FDA Clears Zimmer's Gender Solutions Artificial Knee for Women II-35 Stryker Launches Triathlon Knee System for Women II-35 DePuy Introduces ASR XL Metal-on-Metal Total Hip Replacement Device II-35 Smith & Nephew Introduces New EMPERION* Modular Hip System II-35 FDA Clears Stryker's LFIT(TM) Anatomic Femoral Heads with X3( R) Liners II-36 Wright Medical Unveils CHARLOTTE(TM) Foot & Ankle System II-36 Wright Medical Group Introduces A-CLASS(TM) Advanced Metal II-36 Smith & Nephew Unveils AchieveCAS* for Performing Accurate Knee Implant Procedures II-36 Smith & Nephew Unveils LEGION Revision Knee System with OXINIUM Material II-37 Encore Gains FDA Approval - To Market New Reverse Shoulder Prosthesis(R) II-37 FDA Approves Biomet's C2a-Taper(TM) Ceramic-On- Ceramic Hip System II-37 Biomet Obtains FDA Clearance for ArComXL(TM) II-37 DePuy Orthopedics Introduces New Biologic Shoulder Implant II-38 Zimmer Launches First High Flexion Unicompartmental Knee II-38 DePuy Orthopaedics Introduces Uni-Compartmental Knee Implant II-38 DePuy Orthopaedics Introduces Agility(TM) Total Ankle System II-39 Biomet's Meniscal Unicompartmental System in the US II-39 Smith & Nephew's Uncemented Porous Coated Knees II-39 Smith & Nephew's Bone Graft Substitute II-39 Stryker's Revolutionary Ceramic-on-ceramic Hip Replacement in the US II-39 Wright Medical's Ceramic Hip II-39

9. Recent Industry Activity II-40 Wright Medical to Take Over INBONE Technologies II-40 Encore Medical of DJO Renamed to DJO Surgical II-40 Wright Medical Acquires Foot Surgery Division of DARCO International II-40 Smith & Nephew Acquires Plus Orthopedics II-40 DJO Concludes Merger with ReAble Therapeutics II-41 Wright Medical Purchases Metasurg's Foot and Ankle Implants II-41 Wright Medical Buys External Fixation Product Line of R&R Medical II-41 Regeneration Technologies and Wright Medical Partner to Develop Innovative Implants II-41 Biomet Merges with LVB Acquisition II-41 Kensey Nash and Biomet Sign Exclusive Distribution Agreement II-41 FDA Approves Zimmer(R) NexGen(R) LPS-Flex Mobile Knee II-42 Regeneration Technologies and Zimmer Holdings Ink 10-year Distribution Agreement II-42 Corin and Stryker Enter into a Distribution Concord II-42 Blackstone Capital Partners Inks Definitive Agreement to Acquire Encore II-42 Integra Takes Over KMI in a Cash Transaction II-42 MAKO Licenses New Orthopedic Implant Material Rights from UF II-43 Hanger Acquires Regional Artificial Limb & Brace Co. and Temple Medical II-43 Stryker Enters into Distribution Agreement with Corin Group II-43 Smith & Nephew Inks Exclusive Licensing Agreement with ART for Developing Knee Prosthetic II-43 Encore Medical Takes Over Osteoimplant Technology II-43 Stryker & Wright Medical Award Titanium Powder Contract to AP&C II-44 Corin Group Establishes New Subsidiary in China II-44 Zimmer Completes the Acquisition of Implex II-44 Smith & Nephew Acquires MMT II-44 Exactech Acquires Total Shoulder System of Teknimed II-44 Zimmer Acquires Centerpulse II-45 Hanger Acquires Advanced Bio-Mechanics and Northern Virginia Orthotics & Prosthetics II-45 Virtual Scopics Collaborates with Anderson Orthopaedic Research Institute II-45

10. Focus on Select Players II-46 Biomet, Inc. (US) II-46 Corin Group PLC (UK) II-46 DePuy Orthopedics, Inc. (USA) II-46 DJO Surgical (USA) II-46 Smith & Nephew Plc (UK) II-47 Stryker Corp. (USA) II-47 Wright Medical Group, Inc. (USA) II-48 Zimmer Holdings, Inc. (USA) II-48

11. Global Market Perspective II-49

Table 6: World Recent Past, Current & Future Analysis for Orthopedic Prosthetics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-49

Table 7: World Long-term Projections Orthopedic Prosthetics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-50

Table 8: World Historic Review for Orthopedic Prosthetics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) II-51

Table 9: World 15-Year Perspective for Orthopedic Prosthetics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008, & 2012 (includes corresponding Graph/Chart) II-52

Table 10: World Recent Past, Current & Future Analysis for Hip Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-53

Table 11: Term-term Projections Hip Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-54

Table 12: World Historic Review for Hip Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia- Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) II-55

Table 13: World 15-Year Perspective for Hip Prosthesis by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008,& 2012 (includes corresponding Graph/Chart) II-56

Table 14: World Recent Past, Current & Future Analysis for Knee Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-57

Table 15: WorldLong-term Projections Knee Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia- Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-58

Table 16: World Historic Review for Knee Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includescorresponding Graph/Chart) II-59

Table 17: World 15-Year Perspective for Knee Prosthesis by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008,& 2012 (includes corresponding Graph/Chart) II-60

Table 18: World Recent Past, Current & Future Analysis for Secondary Joint Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-61

Table 19: WorldLong-term Projections Secondary Joint Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-62

Table 20: World Historic Review for Secondary Joint Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) II-63

Table 21: World 15-Year Perspective for Secondary Joint Prosthesis by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008,& 2012 (includes corresponding Graph/Chart) II-64

Table 22: World Recent Past, Current & Future Analysis for Secondary Joint Prosthesis by Product Segment - Shoulder and Other Secondary Joint Prosthesis Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-65

Table 23: World Long-term Projections for Secondary Joint Prosthesis by Product Segment - Shoulder and Other Secondary Joint Prosthesis Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-66

Table 24: World Historic Review for Secondary Joint Prosthesis by by Product Segment - Shoulder and Other Secondary Joint Prosthesis Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) II-67

Table 25: World 15-Year Perspective for Secondary Joint Prosthesis for Secondary Joint Prosthesis by Product Segment - Shoulder and Other Secondary Joint Prosthesis Markets for Years 1998, 2008 & 2012 II-67

Table 26: World Recent Past, Current & Future Analysis for Shoulder Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-68

Table 27: WorldLong-term Projections Shoulder Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-69

Table 28: World Historic Review for Shoulder Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia- Pacific (excluding Japan), Latin America and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) II-70

Table 29: World 15-Year Perspective for Shoulder Prosthesis by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008,& 2012 (includes corresponding Graph/Chart) II-71

Table 30: World Recent Past, Current & Future Analysis Other Secondary Joint Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) II-72

Table 31: World Long-term Projections for Other Secondary Joint Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) II-73

Table 32: World Historic Review for Other Secondary Joint Prosthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) II-74

Table 33: World 15-Year Perspective for Other Secondary Joint Prosthesis by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe,Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 1998, 2008 & 2012 (includes corresponding Graph/Chart) II-75

III. MARKET

1. The United States III-1 A.Market Analysis III-1 Issues & Trends III-1 Rising Demand for Hip and Knee Replacement Surgeries in the US III-1 Advancements in Prosthetic Implants Foster Demand for Joint Replacement Procedures III-2 Reconstructive Products - Growth Drivers III-2 Demographics III-2

Table 34: Percentage of Population in terms of Age Groups in the US (includes corresponding Graph/Chart) III-2

Table 35: Population of the Elderly in the US (in Millions): Population of 50-54, 55-59, 60-64, 65-69 and 70-74 Age Groups for 2001(E), 2006(E) and 2011(E ) (includes corresponding Graph/Chart) III-3 Innovations: Ameliorate Industry Growth III-3 Younger Patients - New Target III-3 Price/Mix Shift III-3 Medicare Reimbursement: A Macro Catalyst III-4 Knee Implants Market III-4

Table 36: Knee Implants Market in the US (2004): Percentage Breakdown by Value Sales for Implant Type - Cemented Femoral, Cemented Tibial, Cementless Femoral,Cementless Tibial and Polyethylene Liner (includes corresponding Graph/Chart) III-4

Table 37: Knee Implant Procedures in the US: 2000- 2007 (In Thousands) (includes corresponding Graph/Chart) III-4 Hip Implants Market III-5 New Materials Emerge as Polyethylene Alternatives III-5

Table 38: Hip Implant Procedures in the US: 2000- 2007 (In Thousands) (includes corresponding Graph/Chart) III-5 Shift from Cemented to Press-Fit Procedures III-5 Major Players III-5

Table 39: Leading Players in the US Hip Implants Market (2004-05): Percentage Breakdown by Value Sales for Zimmer, Depuy, Stryker, Biomet, Smith & Nephew, Wright Medical and Others (includes corresponding Graph/Chart) III-6

Table 40: Leading Players in the US Knee Implants Market (2004-05): Percentage Breakdown by Value Sales for Zimmer, Depuy, Stryker, Biomet, Smith & Nephew, Wright Medical and Others (includes corresponding Graph/Chart) III-6 Product Launches III-7 Strategic Corporate Developments III-18 Key Players III-23 Biomet, Inc. III-23 DePuy Orthopedics, Inc. III-23 DJO Surgical III-23 Exactech, Inc. III-24 Stryker Corporation III-24 Wright Medical Group, Inc. III-25 Zimmer Holdings, Inc. III-25 B.Market Analytics III-26

Table 41: US Recent Past, Current & Future Analysis for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-26

Table 42: US Long-term Projections for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-27

Table 43: US Historic Review for Orthopedic Prosthetics by Product Segment - Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) III-27

Table 44: US 15-Year Perspective for Orthopedic Prosthetics by Product Segment - Percentage Breakdown of Value Sales for Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets for 1998, 2008,& 2012 (includes corresponding Graph/Chart) III-28

2. Canada III-29 Market Analysis III-29 Strategic Corporate Development III-29

Table 45: Canadian Recent Past, Current & Future Market Analysis for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includescorresponding Graph/Chart) III-29

Table 46: Canadian Long-term Projections for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includescorresponding Graph/Chart) III-30

Table 47: Canadian Historic Review for Orthopedic Prosthetics by Product Segment - Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) III-30

Table 48: Canadian 15-Year Perspective for Orthopedic Prosthetics by Product Segment - Percentage Breakdown of Value Sales for Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets for 1998, 2008,& 2012 (includes corresponding Graph/Chart) III-31

3. Japan III-32 A.Market Analysis III-32 Current & Future Analysis III-32 Growth Boosters III-32 Driven by Innovations III-32 Aging Population Propels Sales III-32 Government Resorts to Reimbursement Cuts for Orthopedics Sector III-32 Players in Japanese Orthopedic Implants Market III-33

Table 49: Leading Players in the Japanese Knee Implants Market (2005): Percentage Breakdown by Value Sales for Zimmer, Stryker, DePuy- J&J, Wright Medical Group, Biomet, Smith& Nephew and Others (includes corresponding Graph/Chart) III-33 Product Launch III-33 B.Market Analytics III-34

Table 50: Japanese Recent Past, Current & Future Market Analysis for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million forYears 2001 through 2010 (includes corresponding Graph/Chart) III-34

Table 51: Japanese Long-term Projections for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million forYears 2011 through 2015 (includes corresponding Graph/Chart) III-35

Table 52: Japanese Historic Review for Orthopedic Prosthetics by Product Segment - Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) III-35

Table 53: Japanese 15-Year Perspective for Orthopedic Prosthetics by Product Segment - Percentage Breakdown of Value Sales for Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets for 1998, 2008,& 2012 (includes corresponding Graph/Chart) III-36

4. Europe III-37 A.Market Analysis III-37 Outlook III-37 Demographics Drive Growth III-37 European Hip and Knee Replacement Market III-37 Growth Drivers III-37 Increase in Elderly Population Fuels Demand for Joint Replacement Procedures III-37 Reduced Waiting Time & Effective Clinical Outcomes Boost Industry Prospects III-37 Revision Surgeries - A Major Growth Area III-37 Technological Advancements Ensure Higher Demand for Replacement Procedures III-38 Market Restraints III-38 Reimbursements Scenario in Europe III-38 Competitive Scenario III-38 Trends Driving the Implants Segment III-38

Table 54: Leading Players in European Hip Implants Market (2004): Percentage Breakdown by Value Sales for DePuy/Johnson & Johnson, Stryker, Zimmer, Biomet and Others (includes corresponding Graph/Chart) III-39 Modular Systems Turn the Most Common Form of Knee Implant in Europe III-39

Table 55: Leading Players in European Knee Implants Market (2004): Percentage Breakdown by Value Sales for DePuy- J&J, Zimmer, Stryker, Biomet and Others (includes corresponding Graph/Chart) III-39 B.Market Analytics III-40

Table 56: European Recent Past, Current & Future Market Analysis for Orthopedic Prosthetics by Geographic Region - France, Germany, UK, Italy & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-40

Table 57: European Long-term Projections for Orthopedic Prosthetics by Geographic Region - France, Germany, UK, Italy & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-41

Table 58: European Recent Past, Current & Future Market Analysis for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2010 (includes corresponding Graph/Chart) III-42

Table 59: European Long-term Projections for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-42

Table 60: European Historic Review for Orthopedic Prosthetics by Geographic Region - France, Germany, UK, Italy & Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) III-43

Table 61: European Historic Review for Orthopedic Prosthetics by Product Segment - Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) III-43

Table 62: European 15-Year Perspective for Orthopedic Prosthetics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, UK, Italy & Rest of Europe Markets for Years 1998, 2008,& 2012 (includes corresponding Graph/Chart) III-44

Table 63: European 15-Year Perspective for Orthopedic Prosthetics by Product Segment - Percentage Breakdown of Value Sales for Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets for 1998, 2008,& 2012 (includes corresponding Graph/Chart) III-44

4a. France III-45 A.Market Analysis III-45 Current & Future Analysis III-45 Orthopedic Market in France III-45 Demographics Underpinning Growth III-45

Table 64: Percentage Breakdown of Population by Age Group in France includes corresponding Graph/Chart) III-45 B.Market Analytics III-46

Table 65: French Recent Past, Current & Future Market Analysis for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-46

Table 66: French Long-term Projections for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-46

Table 67: French Historic Review for Orthopedic Prosthetics by Product Segment - Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) III-47

Table 68: French 15-Year Perspective for Orthopedic Prosthetics by Product Segment - Percentage Breakdown of Value Sales for Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets for 1998, 2008,& 2012 (includes corresponding Graph/Chart) III-47

4b. Germany III-48 A.Market Analysis III-48 Orthopedic Products in Germany III-48 Demographic Profile III-48

Table 69: Percentage Breakdown of Population by Age Group in France (includes corresponding Graph/Chart) III-48 Key Players III-48 AAP Implantate AG III-48 Aesculap Implant Systems Inc III-49 B.Market Analytics III-49

Table 70: German Recent Past, Current & Future Analysis for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-49

Table 71: German Long-term Projections Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-50

Table 72: German Historic Review for Orthopedic Prosthetics by Product Segment - Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) III-50

Table 73: German 15-Year Perspective for Orthopedic Prosthetics by Product Segment - Percentage Breakdown of Value Sales for Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets for 1998, 2008,& 2012 (includes corresponding Graph/Chart) III-51

4c. The United Kingdom III-52 A.Market Analysis III-52 Total Hip Replacement Statistics III-52 Shoulder & Small Joint Implants III-52 Demographic Profile III-52

Table 74: Percentage Breakdown of Population by Age Group in UK (includes corresponding Graph/Chart) III-52 Leading Players III-52 Issues & Trends III-53 Aging Baby Boomer Generation Fuels Demand for Knee Replacement Surgeries in the UK III-53 Trends in Primary and Revision Joint (Hip and Knee) Replacement Procedures III-53 Key Players III-53 Corin Group PLC III-53 Finsbury Orthopaedics III-53 Smith & Nephew Plc III-53 B.Market Analytics III-54

Table 75: uk Recent Past, Current & Future Analysis for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2010 (includes corresponding Graph/Chart) III-54

Table 76: uk Long-term Projections Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-55

Table 77: uk Historic Review for Orthopedic Prosthetics by Product Segment - Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) III-55

Table 78: uk 15-Year Perspective for Orthopedic Prosthetics by Product Segment - Percentage Breakdown of Value Sales for Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets for 1998, 2008,& 2012 (includes corresponding Graph/Chart) III-56

4d. Italy III-57 A.Market Analysis III-57 Demographic Profile III-57

Table 79: Percentage Breakdown of Population by Age Group in Italy (includes corresponding Graph/Chart) III-57 B.Market Analytics III-58

Table 80: Italian Recent Past, Current & Future Analysis for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-58

Table 81: Italian Long-term Projections Orthopedic Prostmetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-58

Table 82: Italian Historic Review for Orthopedic Prosthetics by Product Segment - Hip Prosthesis, Knee Prosthesis,and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) III-59

Table 83: Italian 15-Year Perspective for Orthopedic Prosthetics by Product Segment - Percentage Breakdown of Value Sales for Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets for 1998, 2008,& 2012 (includes corresponding Graph/Chart) III-59

4e. Rest of Europe III-60 A.Market Analysis III-60 Overview of Select Markets in Europe III-60 Austria III-60 Czech Republic III-60 Spain III-61 Switzerland III-61 Ukraine III-61 Strategic Corporate Development III-62 B.Market Analytics III-62

Table 84: Rest of Europe Recent Past, Current & Future Analysis for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-62

Table 85: Rest of Europe Long-term Projections Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-63

Table 86: Rest of Europe Market for Orthopedic Prosthetics - Historic Review by Product Segment for Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) III-63

Table 87: Rest of Europe 15-Year Perspective for Orthopedic Prosthetics by Product Segment - Percentage Breakdown of Value Sales for Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets for 1998, 2008,& 2012 (includes corresponding Graph/Chart) III-64

5. Asia-Pacific III-65 A.Market Analysis III-65 Factors Influencing Demand for Joint Replacement Procedures III-65 Hip Implants Market in Asia - Potential for Growth III-65 Declining Reimbursements - Means to Reduce Financial Burden III-65 Overview of Select Markets in Asia III-66 Australia III-66 China III-66 India III-66 Regulatory Impact on Orthopedic Devices Industry III-67 India - A Favored Destination for Low-Cost Orthopedic Surgical Procedures III-67 New Zealand III-67 Government Funding for Increasing Number of Hip and Knee Replacement Surgeries III-67 South Korea III-67 Imports III-68 Competition III-68

Table 88: Leading Players in the Korean Hip Implants Market (2004): Percentage Breakdown by Value Sales for Stryker, Zimmer, Depuy, and Others (includes corresponding Graph/Chart) III-69

Table 89: Leading Players in the Korean Hip Implants Market (2004): Percentage Breakdown by Value Sales for Stryker, Zimmer, Depuy, and Others (includes corresponding Graph/Chart) III-69 Taiwan III-69 Strategic Corporate Developments III-69 B.Market Analytics III-70

Table 90: Asia-Pacific Recent Past, Current & Future Analysis for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-70

Table 91: Asia-Pacific Long-term Projections Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-70

Table 92: Asia-Pacific Market for Orthopedic Prosthetics - Historic Review by Product Segment for Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) III-71

Table 93: Asia-Pacific 15-Year Perspective for Orthopedic Prosthetics by Product Segment - Percentage Breakdown of Value Sales for Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets for 1998, 2008,& 2012 (includes corresponding Graph/Chart) III-71

6. Latin America III-72 Market Analysis III-72

Table 94: Latin American Recent Past, Current & Future Analysis for Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2010 (includes corresponding Graph/Chart) III-72

Table 95: Latin American Long-term Projections Orthopedic Prosthetics by Product Segment -Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart) III-73

Table 96: Latin American Market for Orthopedic Prosthetics - Historic Review by Product Segment for Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 1995 through 2000 (includes corresponding Graph/Chart) III-73

Table 97: Latin American 15-Year Perspective for Orthopedic Prosthetics by Product Segment - Percentage Breakdown of Dollar Sales for Hip Prosthesis, Knee Prosthesis, and Secondary Joint Prosthesis (Shoulder Prosthesis and Other Joint Prosthesis) Markets for 1998, 2008,& 2012 (includes corresponding Graph/Chart) III-74

7. Rest of World III-75 A.Market Analysis III-75 Israel

To order this report: World Orthopedic Prosthetics Market

http://www.reportlinker.com/p090647/World-Orthopedic-Prosthetics-Market.html

More market research reports here!

SOURCE: ReportLinker

Reportlinker 
Nicolas: nbo@reportlinker.com 
US: (805)-652-2626 
Intl: +1 805-652-2626

Biomet, Inc. and its subsidiaries design, manufacture, and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet's product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, autologous therapies and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 90 countries.

SOURCE: Biomet, Inc.

Biomet, Inc. 
Carolyn Beatty, Investor Relations, 574-372-1571 
Barbara Goslee, Corporate Communications, 574-372-1514